This study was designed to detect reticuloendotheliosis virus (REV) as a contaminant in fowl pox vaccines. A total of 30 fowl pox vaccine samples were examined for the presence of REV using both in vitro and in vivo methods. In in vitro testing, the fowl pox vaccine samples were inoculated into chicken embryo fibroblast cultures prepared from specific-pathogen-free embryonated chicken eggs, and the cultures were examined using PCR to detect REV. In in vivo testing, each fowl pox vaccine sample was inoculated into 5-d-old specific-pathogen-free chicks, which were kept under observation for up to 12 wk postinoculation; serum samples were collected at 15, 30, and 45 d postinoculation for the detection of REV-specific antibodies using ELISA. Tissue samples were collected at 8 and 12 wk postinoculation for histopathological examination. Of the tested vaccines, only one imported vaccine sample tested positive for REV using PCR. Serum samples collected from chicks infected with the PCR-positive vaccine batch also tested positive for REV-specific antibodies using ELISA. Histopathological examination of the liver, spleen, and bursa of Fabricius demonstrated the presence of tumor cells in these organs, confirming the results obtained using PCR and ELISA, and indicating that the sample was contaminated with REV. These data clearly indicate that the screening of all commercial poultry vaccines for viruses is an important factor in assuring the biosafety of animal vaccines.
E. coli infections are responsible for great economic losses in the poultry industry worldwide, bringing serious threat to the turkey industry. The present investigation aimed to prepare a potent vaccine from E. coli serogroups O1 and O78 to aid in control of colibacillosis in turkey. One hundred commercial 14 days-old turkey poults were used and divided into three groups; first group was vaccinated twice with 3 weeks interval by prepared inactivated E.coli vaccine adjuvanted with aluminum hydroxide gel, second group was vaccinated twice with 3 weeks interval by prepared inactivated E.coli vaccine adjuvanted with montanide ISA70, third group was left as unvaccinated control one. The immune response was measured by MAT (Microagglutination test), ELISA and challenge test. It was found that the protection rate for inactivated vaccine with aluminum hydroxide gel and E.coli inactivated vaccine with montanide ISA70 were 80% and 85% respectively although it was 30% among the unvaccinated group. ـــــــــــــــــــــــــــــــــــــــــ
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.